Alain Bernard - VectivBio Holding Chief Officer
| VECTDelisted Stock | USD 16.85 0.00 0.00% |
Insider
Alain Bernard is Chief Officer of VectivBio Holding AG
| Age | 66 |
| Phone | 41 61 551 30 3 |
| Web | https://vectivbio.com |
VectivBio Holding Management Efficiency
The company has return on total asset (ROA) of (0.2587) % which means that it has lost $0.2587 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5692) %, meaning that it created substantial loss on money invested by shareholders. VectivBio Holding's management efficiency ratios could be used to measure how well VectivBio Holding manages its routine affairs as well as how well it operates its assets and liabilities.VectivBio Holding AG currently holds 10.46 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. VectivBio Holding has a current ratio of 4.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about VectivBio Holding's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Joseph Tucker | Enveric Biosciences | 55 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| DSc MSE | Immix Biopharma | 75 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| JD MBA | Immix Biopharma | N/A | |
| Nandan BS | Immix Biopharma | 62 | |
| MBA MD | Immix Biopharma | 49 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| MBA IV | Enveric Biosciences | 68 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Gabriel BA | Immix Biopharma | 37 | |
| David Dornan | Elevation Oncology | 46 | |
Management Performance
| Return On Equity | -0.57 | |||
| Return On Asset | -0.26 |
VectivBio Holding Leadership Team
Elected by the shareholders, the VectivBio Holding's board of directors comprises two types of representatives: VectivBio Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VectivBio. The board's role is to monitor VectivBio Holding's management team and ensure that shareholders' interests are well served. VectivBio Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VectivBio Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Luca MD, CEO Founder | ||
| Claudia DAugusta, Chief Officer | ||
| Kevin MBA, Chief Officer | ||
| Christian MD, Chief Officer | ||
| Sarah Holland, Chief Officer | ||
| Alain Bernard, Chief Officer | ||
| Patrick Malloy, VP Communications | ||
| Scott Applebaum, Chief Sec | ||
| Michael Steininger, VP HR | ||
| Omar MD, Chief Officer |
VectivBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VectivBio Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (2.95) % | |||
| Current Valuation | 846.2 M | |||
| Shares Outstanding | 62.81 M | |||
| Shares Owned By Insiders | 4.50 % | |||
| Shares Owned By Institutions | 83.80 % | |||
| Number Of Shares Shorted | 77.6 K | |||
| Price To Book | 3.62 X | |||
| Price To Sales | 21.08 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in VectivBio Stock
If you are still planning to invest in VectivBio Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VectivBio Holding's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |